Microbot Medical (NASDAQ:MBOT) Stock Gets Price Target Trim from Citizens Jmp

Microbot Medical (NASDAQ:MBOT – Free Report) had its price target decreased by Citizens Jmp from $2.50 to $2.00 in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.

A number of other research firms also recently weighed in on MBOT. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Microbot Medical in a research report on Wednesday, October 21st. Wall Street Zen cut Microbot Medical from a “sell” rating to a “strong sell” rating in a research report on Saturday, October 24th. UBS Group set a $2.50 price objective on shares of Microbot Medical in a research note on Friday, October 23rd. Weiss Ratings downgraded shares of Microbot Medical from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Finally, Zacks Research lowered shares of Microbot Medical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 20th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Microbot Medical currently has an average rating of “Moderate Buy” and a consensus price target of $4.83.

View Our Latest Stock Analysis on MBOT

Microbot Medical Trading Up 3.0%

NASDAQ MBOT opened at $0.74 on Tuesday. The company has a 50 day moving average of $1.10 and a 200-day moving average of $1.78. Microbot Medical has a 1-year low of $0.52 and a 1-year high of $2.85.

Microbot Medical (NASDAQ:MBOT – Get Free Report) last issued its quarterly earnings results on Friday, November 13th. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $0.07 million during the quarter, compared to analyst estimates of $0.01 million. Sell-side analysts expect that Microbot Medical will post -0.30 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Microbot Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE lifted its stake in Microbot Medical by 1,688.1% in the 1st quarter. Bank of America Corp DE now owns 75,799 shares of the biotechnology company’s stock valued at $183,000 after purchasing an additional 71,560 shares during the last quarter. Cetera Investment Advisers boosted its position in Microbot Medical by 44.7% in the first quarter. Cetera Investment Advisers now owns 42,412 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 13,099 shares in the last quarter. Private Advisor Group LLC acquired a new stake in Microbot Medical in the first quarter valued at approximately $54,000. Finally, CTC Alternative Strategies Ltd. bought a new stake in shares of Microbot Medical during the first quarter worth $28,000. 16.30% of the stock is currently owned by institutional investors and hedge funds.

About Microbot Medical

(Get Free Report)

Microbot Medical is a medical-device company developing robotic technologies for endovascular procedures. Its work focuses on tools intended to help physicians navigate blood vessels and perform minimally invasive interventions. The company’s lead platform, LIBERTY, is a remotely operated robotic system designed for endovascular procedures. The system is intended to work with guidewires and catheters and to support physicians in controlling these devices during treatment. Microbot Medical is based in the United States and has roots in Israel.

Further Reading

Analyst Recommendations for Microbot Medical (NASDAQ:MBOT)

Receive News & Ratings for Microbot Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Microbot Medical and related companies with MarketBeat.com's FREE daily email newsletter.